Lu, Jiapeng
Yang, Yang
Cui, Jianlan
Xu, Wei
Wu, Chaoqun
Li, Jing
Li, Xi
Article History
Received: 19 November 2021
Accepted: 31 March 2022
First Online: 19 April 2022
Declarations
:
: The central ethics committee at the China National Center for Cardiovascular Disease approved this project. All enrolled participants provided written informed consent. And all methods were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: Dr. Jing Li reported receiving research grants, through Fuwai Hospital, from Chinese government and Chinese Academy of Medical Sciences for work to improve the management of hypertension and blood lipids and to improve patient outcomes of cardiovascular disease and COVID-19; receiving research agreements, through the National Center for Cardiovascular Diseases and Fuwai Hospital, from Amgen for a multicenter clinical trial assessing the efficacy and safety of omecamtiv mecarbil and for dyslipidemic patient registration; receiving a research agreement, through Fuwai Hospital, from Sanofi for a multicenter clinical trial on the effects of sotagliflozin; receiving a research agreement, through Fuwai Hospital, with the University of Oxford for a multicenter clinical trial of empagliflozin; receiving a research agreement, through the National Center for Cardiovascular Diseases, from AstraZeneca for clinical research methods training outside the submitted work; and receiving a research agreement, through the National Center for Cardiovascular Diseases, from Lilly for physician training outside the submitted work. No other disclosures were reported.